Thursday, 15 October 2026European Markets

MAGNORA Stock Bullish By 28% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of MAGNORA (Oslo Børs Benchmark Index_GI: MGN.OL) rose by a staggering 28.51% in 21 sessions from kr22.1 to kr28.40 at 14:41 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 0.29% to kr1,215.57, after three sequential sessions in a row of losses.

MAGNORA's last close was kr28.40, 4.86% under its 52-week high of kr29.85.

About MAGNORA

Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr0.75.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 37.87. Meaning, the purchaser of the share is investing kr37.87 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 331.6%, now sitting on 104.3M for the twelve trailing months.

Sales Growth

MAGNORA's sales growth for the next quarter is 1016.9%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MAGNORA's EBITDA is 17.24.

More news about MAGNORA (MGN.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com